

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Biologic therapies for Crohn&rsquo;s disease:... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1210/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1210" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Biologic therapies for Crohn’s disease: optimising the old and maximising the new" />
    
            <meta name="og:title" content="F1000Research Article: Biologic therapies for Crohn&rsquo;s disease: optimising the old and maximising the new.">
            <meta name="og:description" content="Read the latest article version by Mark Samaan, Samantha Campbell, Georgina Cunningham, Aravind Gokul Tamilarasan, Peter M. Irving, Sara McCartney, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="20718">
            <meta name="article-id" content="18902">
            <meta name="dc.title" content="Biologic therapies for Crohn&rsquo;s disease: optimising the old and maximising the new">
            <meta name="dc.description" content="The era of biologic agents for the treatment of Crohn&rsquo;s disease has brought about significant benefits for patients, and since the introduction of infliximab at the turn of the century, the entire field has moved on rapidly. Clinicians now have multiple agents at their disposal and a choice between several different anti-inflammatory mechanisms of action. This has allowed unprecedented improvements not only in symptoms and quality of life for patients previously refractory to conventional treatments but also for demonstrated healing of the intestinal mucosa and resolution of perianal fistulation. However, despite the undisputed efficacy of these agents, there remains a significant proportion of patients who fail to gain a meaningful benefit. Through years of studying infliximab and its counterpart anti-tumour necrosis factor (anti-TNF) agent, adalimumab, we now understand that strategies such as combining use with a conventional immunomodulator or measuring serum levels can help to optimise outcomes and reduce the proportion of patients for whom treatment fails. Work is ongoing to understand whether these principles apply to newer biologics such as vedolizumab and ustekinumab. In addition, novel approaches are being investigated in an attempt to maximise the benefit that these agents could offer. In this article, we summarise these new understandings and consider ways in which they could be integrated into clinical practice for the benefit of patients.">
            <meta name="dc.subject" content="Crohn&rsquo;s disease, Biologics, Infliximab, Adalimumab, Vedolizumab, Ustekinumab">
            <meta name="dc.creator" content="Samaan, Mark">
            <meta name="dc.creator" content="Campbell, Samantha">
            <meta name="dc.creator" content="Cunningham, Georgina">
            <meta name="dc.creator" content="Tamilarasan, Aravind Gokul">
            <meta name="dc.creator" content="Irving, Peter M.">
            <meta name="dc.creator" content="McCartney, Sara">
            <meta name="dc.date" content="2019/07/29">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.18902.1">
            <meta name="dc.source" content="F1000Research 2019 8:1210">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Crohn&rsquo;s disease">
            <meta name="prism.keyword" content="Biologics">
            <meta name="prism.keyword" content="Infliximab">
            <meta name="prism.keyword" content="Adalimumab">
            <meta name="prism.keyword" content="Vedolizumab">
            <meta name="prism.keyword" content="Ustekinumab">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/07/29">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1210">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.18902.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1210">
            <meta name="citation_title" content="Biologic therapies for Crohn&rsquo;s disease: optimising the old and maximising the new">
            <meta name="citation_abstract" content="The era of biologic agents for the treatment of Crohn&rsquo;s disease has brought about significant benefits for patients, and since the introduction of infliximab at the turn of the century, the entire field has moved on rapidly. Clinicians now have multiple agents at their disposal and a choice between several different anti-inflammatory mechanisms of action. This has allowed unprecedented improvements not only in symptoms and quality of life for patients previously refractory to conventional treatments but also for demonstrated healing of the intestinal mucosa and resolution of perianal fistulation. However, despite the undisputed efficacy of these agents, there remains a significant proportion of patients who fail to gain a meaningful benefit. Through years of studying infliximab and its counterpart anti-tumour necrosis factor (anti-TNF) agent, adalimumab, we now understand that strategies such as combining use with a conventional immunomodulator or measuring serum levels can help to optimise outcomes and reduce the proportion of patients for whom treatment fails. Work is ongoing to understand whether these principles apply to newer biologics such as vedolizumab and ustekinumab. In addition, novel approaches are being investigated in an attempt to maximise the benefit that these agents could offer. In this article, we summarise these new understandings and consider ways in which they could be integrated into clinical practice for the benefit of patients.">
            <meta name="citation_description" content="The era of biologic agents for the treatment of Crohn&rsquo;s disease has brought about significant benefits for patients, and since the introduction of infliximab at the turn of the century, the entire field has moved on rapidly. Clinicians now have multiple agents at their disposal and a choice between several different anti-inflammatory mechanisms of action. This has allowed unprecedented improvements not only in symptoms and quality of life for patients previously refractory to conventional treatments but also for demonstrated healing of the intestinal mucosa and resolution of perianal fistulation. However, despite the undisputed efficacy of these agents, there remains a significant proportion of patients who fail to gain a meaningful benefit. Through years of studying infliximab and its counterpart anti-tumour necrosis factor (anti-TNF) agent, adalimumab, we now understand that strategies such as combining use with a conventional immunomodulator or measuring serum levels can help to optimise outcomes and reduce the proportion of patients for whom treatment fails. Work is ongoing to understand whether these principles apply to newer biologics such as vedolizumab and ustekinumab. In addition, novel approaches are being investigated in an attempt to maximise the benefit that these agents could offer. In this article, we summarise these new understandings and consider ways in which they could be integrated into clinical practice for the benefit of patients.">
            <meta name="citation_keywords" content="Crohn&rsquo;s disease, Biologics, Infliximab, Adalimumab, Vedolizumab, Ustekinumab">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Mark Samaan">
            <meta name="citation_author_institution" content="Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK">
            <meta name="citation_author" content="Samantha Campbell">
            <meta name="citation_author_institution" content="Department of Gastroenterology, Royal Free London NHS Foundation Trust, London, UK">
            <meta name="citation_author" content="Georgina Cunningham">
            <meta name="citation_author_institution" content="Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK">
            <meta name="citation_author" content="Aravind Gokul Tamilarasan">
            <meta name="citation_author_institution" content="Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK">
            <meta name="citation_author" content="Peter M. Irving">
            <meta name="citation_author_institution" content="Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK">
            <meta name="citation_author" content="Sara McCartney">
            <meta name="citation_author_institution" content="Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK">
            <meta name="citation_publication_date" content="2019/07/29">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1210">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.18902.1">
            <meta name="citation_firstpage" content="1210">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1210/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1210.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=20718 /> <input type=hidden id=articleId name=articleId value=18902 /> <input type=hidden id=xmlUrl value="/articles/8-1210/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1210-v1.xml"> <input type=hidden id=article_uuid value=ab6d8447-6e3d-4647-9264-28fb5517b7dd /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Biologic therapies for Crohn’s disease: optimising the old and maximising the new"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.18902.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.18902.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1210"
  },
  "headline": "Biologic therapies for Crohn’s disease: optimising the old and maximising the new",
  "datePublished": "2019-07-29T11:30:13",
  "dateModified": "2019-07-29T11:30:13",
  "author": [
    {
      "@type": "Person",
      "name": "Mark Samaan"
    },    {
      "@type": "Person",
      "name": "Samantha Campbell"
    },    {
      "@type": "Person",
      "name": "Georgina Cunningham"
    },    {
      "@type": "Person",
      "name": "Aravind Gokul Tamilarasan"
    },    {
      "@type": "Person",
      "name": "Peter M. Irving"
    },    {
      "@type": "Person",
      "name": "Sara McCartney"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The era of biologic agents for the treatment of Crohn&rsquo;s disease has brought about significant benefits for patients, and since the introduction of infliximab at the turn of the century, the entire field has moved on rapidly. Clinicians now have multiple agents at their disposal and a choice between several different anti-inflammatory mechanisms of action. This has allowed unprecedented improvements not only in symptoms and quality of life for patients previously refractory to conventional treatments but also for demonstrated healing of the intestinal mucosa and resolution of perianal fistulation. However, despite the undisputed efficacy of these agents, there remains a significant proportion of patients who fail to gain a meaningful benefit. Through years of studying infliximab and its counterpart anti-tumour necrosis factor (anti-TNF) agent, adalimumab, we now understand that strategies such as combining use with a conventional immunomodulator or measuring serum levels can help to optimise outcomes and reduce the proportion of patients for whom treatment fails. Work is ongoing to understand whether these principles apply to newer biologics such as vedolizumab and ustekinumab. In addition, novel approaches are being investigated in an attempt to maximise the benefit that these agents could offer. In this article, we summarise these new understandings and consider ways in which they could be integrated into clinical practice for the benefit of patients."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1210",
            "name": "Biologic therapies for Crohn’s disease: optimising the old and maximising..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Biologic therapies for Crohn’s disease: optimising the old and maximising... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=20718 data-id=18902 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18902.1" data-recommended="" data-doi="10.12688/f1000research.18902.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1210/v1/pdf?article_uuid=ab6d8447-6e3d-4647-9264-28fb5517b7dd" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-18902-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-18902-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-18902-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Samaan M, Campbell S, Cunningham G <em>et al.</em> Biologic therapies for Crohn’s disease: optimising the old and maximising the new [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1210 (<a class=new-orange href="https://doi.org/10.12688/f1000research.18902.1" target=_blank>https://doi.org/10.12688/f1000research.18902.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-18902-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=18902 id=track-article-signin-18902 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18902?target=/articles/8-1210">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20718 /> <input name=articleId type=hidden value=18902 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Biologic therapies for Crohn’s disease: optimising the old and maximising the new</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:markasamaan@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Mark Samaan</span></a><a href="https://orcid.org/0000-0002-4057-9200" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4057-9200</div><sup>1</sup>,&nbsp;</span><span class="">Samantha Campbell<sup>2</sup>,&nbsp;</span><span class="">Georgina Cunningham<sup>3</sup>,&nbsp;</span><span class="">Aravind Gokul Tamilarasan<sup>3</sup>,&nbsp;</span><span class="">Peter M. Irving<sup>3</sup>,&nbsp;</span><span class=""><a href="mailto:Sara.mccartney@nhs.net" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sara McCartney</span></a><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:markasamaan@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Mark Samaan</span></a><a href="http://orcid.org/0000-0002-4057-9200" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4057-9200</div><sup>1</sup>,&nbsp;</span><span class="">Samantha Campbell<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Georgina Cunningham<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Aravind Gokul Tamilarasan<sup>3</sup>,&nbsp;</span><span class="">Peter M. Irving<sup>3</sup>,&nbsp;</span><span class=""><a href="mailto:Sara.mccartney@nhs.net" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sara McCartney</span></a><sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 29 Jul 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.18902.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK<br/> <sup>2</sup> Department of Gastroenterology, Royal Free London NHS Foundation Trust, London, UK<br/> <sup>3</sup> Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK<br/> <p> <div class=margin-bottom> Mark Samaan <br/> <span>Roles: </span> Conceptualization, Project Administration, Writing – Original Draft Preparation </div> <div class=margin-bottom> Samantha Campbell <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Georgina Cunningham <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Aravind Gokul Tamilarasan <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Peter M. Irving <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Sara McCartney <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=37475-51727></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=54303-51750></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The era of biologic agents for the treatment of Crohn’s disease has brought about significant benefits for patients, and since the introduction of infliximab at the turn of the century, the entire field has moved on rapidly. Clinicians now have multiple agents at their disposal and a choice between several different anti-inflammatory mechanisms of action. This has allowed unprecedented improvements not only in symptoms and quality of life for patients previously refractory to conventional treatments but also for demonstrated healing of the intestinal mucosa and resolution of perianal fistulation. However, despite the undisputed efficacy of these agents, there remains a significant proportion of patients who fail to gain a meaningful benefit. Through years of studying infliximab and its counterpart anti-tumour necrosis factor (anti-TNF) agent, adalimumab, we now understand that strategies such as combining use with a conventional immunomodulator or measuring serum levels can help to optimise outcomes and reduce the proportion of patients for whom treatment fails. Work is ongoing to understand whether these principles apply to newer biologics such as vedolizumab and ustekinumab. In addition, novel approaches are being investigated in an attempt to maximise the benefit that these agents could offer. In this article, we summarise these new understandings and consider ways in which they could be integrated into clinical practice for the benefit of patients. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Crohn’s disease, Biologics, Infliximab, Adalimumab, Vedolizumab, Ustekinumab </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Mark Samaan (<a href="mailto:markasamaan@gmail.com">markasamaan@gmail.com</a>) <br> Sara McCartney (<a href="mailto:Sara.mccartney@nhs.net">Sara.mccartney@nhs.net</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Mark Samaan, Sara McCartney </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> MAS has received advisory fees from Takeda, Janssen, and Falk and lecture fees from Takeda, MSD, Janssen, and Falk. PMI has received advisory fees from Abbvie, Warner Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira, and Samsung Bioepis; lecture fees from Abbvie, Warner Chilcott, Ferring, Falk Pharma, Takeda, MSD, Johnson & Johnson, and Shire; and financial support for research from MSD and Takeda. SM has received advisory fees from Abbvie and MSD. SC, GC, and AGT declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Samaan M <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Samaan M, Campbell S, Cunningham G <em>et al.</em> Biologic therapies for Crohn’s disease: optimising the old and maximising the new [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1210 (<a href="https://doi.org/10.12688/f1000research.18902.1" target=_blank>https://doi.org/10.12688/f1000research.18902.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 29 Jul 2019, <b>8</b>(F1000 Faculty Rev):1210 (<a href="https://doi.org/10.12688/f1000research.18902.1" target=_blank>https://doi.org/10.12688/f1000research.18902.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 29 Jul 2019, <b>8</b>(F1000 Faculty Rev):1210 (<a href="https://doi.org/10.12688/f1000research.18902.1" target=_blank>https://doi.org/10.12688/f1000research.18902.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d19351e221>Introduction</h2><p class="" id=d19351e224>In the two decades since the advent of infliximab (IFX) for the treatment of Crohn’s disease (CD), biologic therapies have delivered substantial improvements in outcomes for patients with inflammatory bowel disease (IBD). Not only can they improve symptoms (resulting in demonstrably improved quality of life) but they also resolve inflammation, judged objectively using endoscopic, radiological or biochemical measures. In addition, biologic therapies have significantly changed the way in which perianal CD is managed and are currently our most effective pharmacological class of drugs for this particularly debilitating manifestation. The US Food and Drug Administration’s approval of IFX for CD in 1998 was followed 9 years later by the approval of adalimumab (ADA) and certolizumab (although IFX and ADA were subsequently approved in Europe, certolizumab was not). For several years, these agents with their common anti-tumour necrosis factor (anti-TNF) mechanism formed the entirety of the licensed biologic options available for CD. However, in recent years, the range of agents and mechanisms of action has expanded. First, in 2014, the selective leukocyte adhesion molecule inhibitor, vedolizumab (VDZ), was approved for use in ulcerative colitis (UC) as well as CD. This was followed in 2016 by the approval (for CD only) of ustekinumab (UST), a monoclonal antibody that targets the p40 subunit of interleukin-12 and interleukin-23. In addition to these new agents, the number of licensed treatments has been further expanded by the growing range of IFX and ADA biosimilar agents now available.</p><p class="" id=d19351e227>Whilst the large-scale registration trials by which the anti-TNF agents were granted their approvals clearly demonstrated their efficacy, it has taken many years and dedicated studies for us to gain a deeper understanding of how they should be used for maximum benefit. Examples include the benefit of their use in combination with a conventional immunosuppressant and introducing them earlier in the disease course as well as the use of therapeutic drug monitoring (TDM) for dose optimisation. Advances in our appreciation of these concepts have allowed practice to evolve to provide improved patient outcomes. Attention is now turning to investigating whether similar concepts will apply to newer biologic agents. In this review, we aim to draw together emerging data which provides new understanding of the optimal use of established agents and to consider how the impact of more novel biologics could potentially be optimised.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19351e233>Anti-tumour necrosis factor: old mechanism, new understandings</h2><div class=section><a name=d19351e236 class=n-a></a><h3 class=section-title>Infliximab</h3><p class="" id=d19351e241><b><i>Dosing regimen modification.</i></b> Standard dosing for IFX induction is a 5-mg/kg intravenous infusion at weeks 0, 2 and 6 and then every 8 weeks thereafter. However, there are a number of ways that this dosing regimen can be modified to optimise an individual’s therapy. In patients with low IFX trough levels (and absent or low-titre anti-drug antibodies) during maintenance therapy, intensifying IFX dosing can improve clinical outcomes and increase the number of patients achieving clinical response<sup><a href="#ref-1">1</a></sup>. This may be achieved either by increasing each infusion to 10 mg/kg or by shortening the dosing interval to either 4 or 6 weeks. Ideally, decisions regarding dose adjustment should be made with the benefit of TDM, inclusive of anti-drug antibody measurement. This is in view of the commonly encountered clinical scenarios for which dose intensification has less rationale. An example is active disease due to the development of high-titre antibodies with sub-therapeutic trough levels (immune-mediated pharmacokinetic failure) or adequate trough levels without antibodies (mechanistic/pharmacodynamic failure), which may warrant a change in therapy rather than dose intensification<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d19351e255>At the opposite end of the spectrum, patients in deep remission on IFX maintenance with supra-therapeutic trough levels could de-escalate their dosing, as relapse rates have been demonstrated to be low<sup><a href="#ref-1">1</a>,<a href="#ref-3">3</a></sup>. Again, this may be done by lengthening the inter-dose interval or reducing the concentration of the infusion (if previously receiving 10 mg/kg). The Trough Level Adapted Infliximab Treatment (TAXIT) study showed that dose reduction (targeting a trough level of 3 to 7 µg/mL) results in a similar proportion of patients in remission but with a 28% reduction in the associated drug costs<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d19351e269>Pregnancy presents another situation in which the dosing regimen of biologic agents may be modified. In this scenario, the aim of modification is usually to maintain the beneficial effect of treatment while attempting to limit exposure to the infant. It is known that both IFX and ADA can cross the placenta from the latter part of the second trimester<sup><a href="#ref-4">4</a></sup>. Therefore, in the setting of a sustained remission, many clinicians recommend temporary discontinuation from this point until after delivery. However, where there is evidence of ongoing disease activity or in the setting of previously refractory or complex disease, the risk-benefit often favours continuing treatment throughout. Although the mechanisms which allow IFX and ADA to cross the placenta are efficient enough to result in up to fourfold higher levels in infant and cord blood compared with maternal levels<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>, this does not appear to adversely affect the developing infant in the short term<sup><a href="#ref-7">7</a></sup>. Therefore, any putative benefit of reducing infant exposure should be balanced with the risks of an intra- or post-partum disease flare, of which there exists conflicting evidence. de Lima <i>et al</i>. reported no difference in relapse rates in women with sustained remission who stopped anti-TNF treatment before week 25 compared with those who continued therapy beyond week 30 (9.8% versus 15.6%, <i>P</i> = 0.14)<sup><a href="#ref-8">8</a></sup>. By contrast, a study by Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives (GETAID) observed a relatively high intra-partum (14%) or early post-partum (32%) relapse rate in mothers who discontinued therapy before week 30<sup><a href="#ref-9">9</a></sup>. Where treatment is continued throughout pregnancy, recent evidence has shown that maternal IFX levels rise whilst ADA levels remain stable (after accounting for changes in albumin, body mass index and C-reactive protein [CRP]). It has therefore been suggested that TDM performed during the second trimester may help guide dosing during the third<sup><a href="#ref-10">10</a></sup>.</p><p class="" id=d19351e306>On balance, for patients who have disease requiring biologic therapy and who are contemplating pregnancy, ADA appears preferable to IFX<sup><a href="#ref-11">11</a></sup>. This is on the basis that rates of transportation of ADA across the placenta are lower<sup><a href="#ref-12">12</a></sup> and that it is cleared more quickly from the circulation of infants than IFX<sup><a href="#ref-7">7</a></sup>. Nonetheless, it is important for clinicians and pregnant patients to be aware that European consensus recommends that live vaccines be avoided until after 6 months in infants exposed to anti-TNF <i>in utero</i><sup><a href="#ref-13">13</a></sup>. There are clearly far less data guiding how best to manage more novel biologics, such as VDZ and UST, during pregnancy. Although both agents are expected to cross the placenta in a manner similar to that of IFX and ADA, there has so far been no evidence of harm<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>. However, further studies are required to better understand their safety and pharmacokinetics during this period.</p><p class="" id=d19351e335><b><i>Measuring and monitoring.</i></b> As is now widely appreciated, trough levels of IFX have been shown to correlate with clinical response, mucosal healing, and clinical remission. The TAXIT study established that targeting IFX trough levels to 3 to 7 µg/mL resulted in more efficient use of the drug<sup><a href="#ref-1">1</a></sup>. An analysis of trough-level thresholds showed a progressive reduction in the proportion of patients not achieving remission at lower levels. The rates decreased from 25% at a level of at least 1 µg/mL to 15% for those with a level of at least 3 µg/mL, 8% for levels of at least 5 µg/mL and 4% for at least 7 µg/mL. Taking into account these data in addition to several other studies, the American Gastroenterological Association (AGA) made a “conditional” recommendation that at least 5 µg/mL should be the target for IFX trough concentrations<sup><a href="#ref-16">16</a></sup>. However, it should be noted that TDM comprises just one aspect of monitoring in an attempt to maintain tight disease control and that dosing regimen modifications should be tailored to the individual. Moreover, although many clinicians advocate proactive TDM<sup><a href="#ref-17">17</a></sup> (that is, dose adjustments based on TDM in asymptomatic patients), there currently exist little direct data to recommend this strategy. Indeed, the first published randomised trial (Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease, or TAILORIX) of proactive versus reactive (that is, in response to symptoms) dose adjustment strategies found no difference between the two<sup><a href="#ref-18">18</a></sup>.</p><p class="" id=d19351e357>One subset of patients that warrants separate discussion consists of the patients who have fistulating disease. It has been shown that higher IFX trough levels are associated with perianal fistula healing in both adults and children<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup>. Yarur <i>et al</i>. performed a cross-sectional study showing that median IFX levels amongst patients with fistula healing were significantly higher than those without fistula healing (15.8 versus 4.4 µg/mL)<sup><a href="#ref-20">20</a></sup>. When levels were stratified by quartiles, a linear association between IFX trough levels and fistula healing was observed. In addition, the absence of anti-drug antibodies was shown to correlate with healing. The optimal levels for fistula healing were at least 10 µg/mL and some patients even required levels of at least 20 µg/mL<sup><a href="#ref-20">20</a></sup>. These findings suggest that trough levels that would usually be considered sufficient for the treatment of luminal disease may be inadequate to achieve fistula healing. Although current evidence does not suggest a relationship between drug exposure and adverse events<sup><a href="#ref-21">21</a></sup>, the safety of such high trough levels has not yet been confirmed in large or longitudinal cohorts.</p><p class="" id=d19351e382><b><i>Combination with a conventional immunosuppressant.</i></b> The immunogenicity of IFX and its clinical implications have been well established for some time. A recent review article analysing 114 studies reported that IFX immunogenicity rates ranged from 0 to 65.3% and were slightly higher for CD than UC<sup><a href="#ref-22">22</a></sup>. In addition, the proportions of patients achieving and maintaining a response were lower in those patients with detected anti-drug antibodies. Other outcomes, including adverse event data (for example, rates of infusion reactions) and trough IFX levels, were superior in those who did not develop anti-drug antibodies<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d19351e396>Robust data generated by the Study of Biologic and Immunomodulator Naive Patients in Crohn’s Disease (SONIC) trial demonstrated that combination therapy with azathioprine achieves higher remission rates in CD<sup><a href="#ref-23">23</a></sup>. Recent observational and randomised studies, in abstract form, have shown that combination therapy reduces the rates of immunogenicity. A large, prospective, observational UK-wide study from the Personalised Anti-TNF Therapy in Crohn’s disease (PANTS) investigator consortium showed immunogenicity rates for IFX (Remicade) of 26% at week 54 and 42% at 3 years (and similar results were seen for the IFX biosimilar CT-P13). These rates were reduced with immunomodulator use (hazard ratio (HR) = 0.37, <i>P</i> &lt;0.0001)<sup><a href="#ref-24">24</a></sup>. Similarly, a recent randomised study showed that in those who failed ADA because of anti-drug antibody development, use of combination therapy (with azathioprine) when starting IFX significantly lowered the risk of immunogenicity<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d19351e414>Perhaps more compelling than short- and medium-term efficacy studies were the findings of the Randomized Evaluation of an Algorithm for Crohn’s Treatment (REACT) study, a cluster randomisation trial of treatment strategies<sup><a href="#ref-26">26</a></sup>. This demonstrated that early combined immunosuppression was associated with a reduced rate of major adverse outcomes (surgery, hospital admission or serious disease-related complications) compared with conventional management (27.7% and 35.1%, absolute difference 7.3%, HR 0.73, 95% confidence interval 0.62 to 0.86, <i>P</i> = 0.0003).</p><p class="" id=d19351e424>In summary, the high rates of IFX immunogenicity observed in the literature and the associated poorer clinical outcomes appear to offer support for the use of combination therapy wherever possible. More recently, a post-hoc analysis of the SONIC trial suggested that the benefit of adding azathioprine to IFX could be explained solely by the resulting increment in IFX serum concentrations rather than the additive immunosuppressive effect of azathioprine<sup><a href="#ref-27">27</a></sup>. In keeping with this, a subsequent prospective study observed that optimised IFX monotherapy is as effective as optimised combination therapy<sup><a href="#ref-28">28</a></sup>. However, the IFX monotherapy group required significantly higher rates of treatment escalation, which makes this strategy unfavourable on a cost-effectiveness basis. </p></div><div class=section><a name=d19351e436 class=n-a></a><h3 class=section-title>Adalimumab</h3><p class="" id=d19351e441><b><i>Dosing regimen modification.</i></b> Currently, the approved dosing schedule for ADA is to give 160 mg followed by 80 mg two weeks later and then a maintenance dose of 40 mg every two weeks. Unfortunately, there is still a proportion of patients who do not respond to or lose response to ADA. In patients who do not respond, increasing the dosing frequency to once a week has been shown to be effective in recapturing response in CD<sup><a href="#ref-29">29</a></sup>. However, to date, the data regarding dose escalation of ADA have been retrospective. To assess this prospectively, the Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease (SERENE-CD) trial has randomly assigned patients to receive higher induction and maintenance doses to establish whether primary and secondary loss of response can be avoided by maintaining higher serum drug concentrations from the outset<sup><a href="#ref-30">30</a></sup>. If a benefit is observed, this may lead to a change in the approved dosing regimen.</p><p class="" id=d19351e455><b><i>Measuring and monitoring.</i></b> Higher concentrations of serum drug are associated with better outcomes, not only clinical remission but also endoscopic healing and deeper histological remission<sup><a href="#ref-31">31</a></sup>. However, for ADA, unlike for IFX, there is evidence to suggest that it may not need to be a trough level that is taken. Ward <i>et al</i>. performed a prospective observational study on 19 patients with CD on maintenance ADA and took serum levels at multiple intervals during the usual 14-day cycle<sup><a href="#ref-32">32</a></sup>. From this, the authors concluded that although ideally a trough levels should be taken, if a level of at least 4.9 μg/mL is detected during the first 9 days following a dose, it can reasonably predict an adequate trough level<sup><a href="#ref-32">32</a></sup>. A recent retrospective study including 382 patients with IBD (311 of whom had CD) found that proactive TDM may be associated with a lower risk of ADA treatment failure compared with standard of care (defined here as either reactive TDM or empirical dose escalation)<sup><a href="#ref-33">33</a></sup>. However, a prospective randomised trial directly comparing these groups (to mirror the TAILORIX trial in IFX) has yet to be conducted.</p><p class="" id=d19351e480>For their 2017 guidelines, the AGA reviewed data from four studies that reported the proportion of patients not in remission above ADA trough concentrations of 5 ± 1 or 7.5 ± 1 µg/mL. This proportion progressively decreased from 17% at a threshold of 5 µg/mL to 10% at a threshold of 7.5 µg/mL. They therefore gave a “conditional” recommendation for the use of 7.5 µg/mL as the target trough concentration<sup><a href="#ref-16">16</a></sup>.</p><p class="" id=d19351e487><b><i>Combination with a conventional immunosuppressant.</i></b> There are varying results from real-world cohort studies in terms of the effect of concomitant immunomodulator therapy on response rates to ADA. Previously, it was felt that the addition of immunomodulators offered no additional benefit in terms of prevention of anti-drug antibodies<sup><a href="#ref-34">34</a></sup>. However, recent data from PANTS demonstrated that immunomodulators significantly reduce the immunogenicity of ADA (HR = 0.34, <i>P</i> &lt;0.0001)<sup><a href="#ref-24">24</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19351e508>Newer mechanisms: tips and tricks</h2><div class=section><a name=d19351e511 class=n-a></a><h3 class=section-title>Vedolizumab</h3><p class="" id=d19351e516><b><i>Dosing regimen modification.</i></b> The induction and maintenance dosing schedule for VDZ involve an intravenous infusion at weeks 0, 2 and 6 and then every 8 weeks. The dose is standardised at 300 mg per infusion and is not weight-based like IFX. There is scope for variation in the maintenance dosing of VDZ to every 4 or 6 weeks, especially in those who are secondary non-responders. A 15% relapse rate was observed in one study that switched patients from every-4-week to every-8-week VDZ (and appears similar between UC and CD). Upon dose intensification back to every 4 weeks, 80% re-entered remission<sup><a href="#ref-35">35</a></sup>. This suggests that, in patients with CD, increasing dose frequency of VDZ to every 4 weeks could lead to an improvement. A recent meta-analysis echoed these findings of dose escalation to recapture response in secondary non-responders<sup><a href="#ref-36">36</a></sup>. The results revealed that a high proportion of patients with CD were secondary non-responders (47.9 per 100 patient-years) and that 56 (50%) out of 111 of secondary non-responders re-entered remission upon dose escalation<sup><a href="#ref-36">36</a></sup>. An observational cohort study of 36 patients with IBD (18 with UC and 18 with CD) with a previous suboptimal response to every-8-week dosing also demonstrated a significant reduction in CRP (from 6 to 2 mg/L, <i>P</i> = 0.011) after 24 weeks of every-4-week dosing (<a href="#f1">Figure 1</a>)<sup><a href="#ref-37">37</a></sup>. The reality of dose intensification with VDZ, although it is within licence, is that, in some healthcare systems, effectively doubling the cost of an already-high-cost drug is considered prohibitively expensive. The cost differential, in recent years, has become even more marked when comparing dose-intensified VDZ with biosimilar agents.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20718/fb311565-abf4-4338-8336-dd32e1604e5a_figure1.gif"><img alt="fb311565-abf4-4338-8336-dd32e1604e5a_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20718/fb311565-abf4-4338-8336-dd32e1604e5a_figure1.gif"></a><div class=caption><h3>Figure 1. Change in C-reactive protein (CRP) following vedolizumab dose intensification.</h3><p id=d19351e555>Vedolizumab dosing interval shortened from every 8 weeks to every 4 weeks among 36 inflammatory bowel disease patients with a previously suboptimal response. IQR, interquartile range. *denotes statistical significance (<i>P</i> &lt; 0.05).</p></div></div><p class="" id=d19351e565>Analysis of patients in GEMINI II and III studies, who had an inadequate response at week 6 and received an additional infusion at week 10, suggested that this may improve chances of remission at week 52<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. Therefore, this optional addition to the standard induction regimen was included in the licence and should be integrated into clinical practice algorithms.</p><p class="" id=d19351e575><b><i>Measuring and monitoring.</i></b> A personalised treatment regimen with VDZ using a targeted therapeutic windows and drug levels requires further research. Unlike for anti-TNF agents, it is not yet a well-established tool used by clinicians as a guide for dose adjustment. Despite studies that have demonstrated that there may be potential value of TDM, the lack of unequivocal supporting data means that most changes in dose frequency are currently made empirically<sup><a href="#ref-35">35</a></sup>. To help guide response to induction and maintenance dosing, we recommend checking objective markers of disease activity at weeks 0 and 14. Ideally, this would include a clinical disease index score and faecal calprotectin and CRP measurements. In CD, additional monitoring at week 6 will help to determine the need for an extra dose at week 10.</p><p class="" id=d19351e586>A dose-response relationship for VDZ was observed in the GEMINI I, II and III studies. Drug level quartile analysis demonstrated a significantly higher rate of clinical response and remission, amongst patients the highest drug level quartile, compared to the lowest<sup><a href="#ref-38">38</a>–<a href="#ref-40">40</a></sup>. This observation was apparent during both the induction and maintenance phases of treatment. Subsequent literature suggests that week 6 drug level monitoring is a relevant predictor of remission or of the need for subsequent dose intensification<sup><a href="#ref-41">41</a>–<a href="#ref-43">43</a></sup>. One study reported that a week 6 level of over 20 µg/mL may be associated with improved clinical outcomes<sup><a href="#ref-35">35</a></sup>. Another observed an association between a week 6 level of over 18 µg/mL and increased rates of mucosal healing<sup><a href="#ref-43">43</a></sup>. The same study examined mucosal healing at week 52 compared with trough levels at weeks 2 and 14 (in addition to week 6), and only week 6 levels showed an association with mucosal healing<sup><a href="#ref-43">43</a></sup>. Drug levels and outcomes vary in the supporting literature and need further validation in larger prospective studies. Until data from larger studies are available, VDZ should be administered with dose optimisation based on objective measures of disease activity.</p><p class="" id=d19351e615><b><i>Combination with a conventional immunosuppressant.</i></b> In patients who receive VDZ, the development of antibodies appears to be low (&lt;5%). This degree of immunogenicity appears unlikely to have a significant impact on clinical outcomes and may decrease over time<sup><a href="#ref-38">38</a>–<a href="#ref-41">41</a>,<a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. GEMINI II and III studies reported immunogenicity rates of 4.1% and 1%, respectively. GEMINI II found persistent antibodies in just 0.4%, whereas GEMINI III found no persisting antibodies. Although these measurements were performed by using a drug-sensitive assay (and therefore were unable to detect antibodies in the presence of drug), the results have been broadly corroborated in other studies using drug-tolerant assays<sup><a href="#ref-45">45</a></sup>. Studies testing samples with drug-tolerant assays found low immunogenicity rates of 17% (7 of 41 patients) during the induction phase, 3% during the maintenance phase and 2.2% (4 of 179) after the first infusion<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. When antibody development was demonstrated in the induction phase, 3 of the 7 responded to induction therapy<sup><a href="#ref-45">45</a></sup>. The transient phenomenon of immunogenicity using VDZ is supported by undetectable antibody burden by week 40 when detected after first infusion<sup><a href="#ref-44">44</a></sup>. The literature therefore supports low immunogenicity rates in treatment with VDZ and shows that antibody development is unlikely to have a significant impact on clinical outcomes.</p><p class="" id=d19351e653>Based on the majority of current evidence, combination therapy with immunomodulators to solely prevent immunogenicity does not appear to be a necessary strategy with VDZ. This is highlighted in a study that analysed pharmacokinetics and pharmacodynamics which demonstrated that the clearance and concentration of VDZ were not affected when co-administered with other immunomodulators<sup><a href="#ref-46">46</a></sup>. An integrated summary of VDZ suggests that whilst its low rates of immunogenicity could be further reduced by concomitant use of immunomodulators, the long-term risk-benefit should be evaluated and may not be in favour of their use<sup><a href="#ref-47">47</a></sup>. This risk-benefit analysis is clearly different from that of IFX, which has much higher rates of immunogenicity. The only note of caution in this regard is that there has been no dedicated randomised study comparing combination therapy with VDZ alone to provide a more definitive answer to this question.</p><p class="" id=d19351e664>VDZ appears to have a more gradual onset of action than other biologic agents, so initiation of treatment often requires bridging with other agents, at least until the end of induction. Corticosteroids are ideally placed to fulfil this role, but in those who are refractory, bridging with calcineurin inhibitors has been shown to be safe and effective<sup><a href="#ref-48">48</a></sup>. They can also aid in maintaining remission up to 52 weeks. In a study where calcineurin inhibitors were used alongside VDZ, 44% of patients with CD had achieved steroid-free remission at week 14<sup><a href="#ref-48">48</a></sup>. This study had a small cohort and further studies are warranted.</p></div><div class=section><a name=d19351e676 class=n-a></a><h3 class=section-title>Ustekinumab</h3><p class="" id=d19351e681><b><i>Real-world effectiveness data.</i></b> In addition to the randomised controlled trial data of ustekinumab’s efficacy demonstrated by the UNITI program, there exists a growing body of observational data of its effectiveness in clinical practice. One such study, carried out as a collaboration between three IBD centres in London, included a cohort of 149 patients and reported week 32 response and remission rates of 63% and 39%, respectively<sup><a href="#ref-49">49</a></sup>. These are broadly consistent with another large cohort (n = 167) from Canada which described corresponding week 24 rates of 60% and 25%<sup><a href="#ref-50">50</a></sup>. The London cohort also reported a range of other endpoints, including biological response (50% reduction in CRP) and biological remission (CRP of less than 5 mg/L in patients with a baseline CRP of more than 5 mg/L) (<a href="#f2">Figure 2</a>)<sup><a href="#ref-49">49</a></sup>.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20718/fb311565-abf4-4338-8336-dd32e1604e5a_figure2.gif"><img alt="fb311565-abf4-4338-8336-dd32e1604e5a_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20718/fb311565-abf4-4338-8336-dd32e1604e5a_figure2.gif"></a><div class=caption><h3>Figure 2. Clinical and biological outcomes at weeks 8 and 32 of 149 patients who received ustekinumab.</h3><p id=d19351e712>Biological remission is defined as C-reactive protein (CRP) of less than 5 mg/L in patients with a baseline CRP of more than 5 mg/L. Biological response is defined as a 50% reduction in CRP. Remission is defined as a Harvey–Bradshaw index (HBI) score of less than 5 points. Response is defined as reduction in HBI score of at least 3 points or sustained HBI score of less than 5 points.</p></div></div><p class="" id=d19351e719><b><i>Dosing regimen modification.</i></b> The induction dosing schedule for UST is fixed and involves an intravenous infusion of 6 mg/kg at week 0 followed by a subcutaneous 90-mg dose at week 8. There is scope for variation in the frequency of maintenance dosing. Depending on response, subsequent 90-mg subcutaneous maintenance doses are given every 8 or 12 weeks. The maintenance dosing regimen of UST, unlike that of other biologics, is guided by an assessment of response to induction therapy. This requirement encourages good clinical practice. However, it can pose certain difficulties and requires additional investigations.</p><p class="" id=d19351e725>To establish adequacy of response to UST induction, a review at or just prior to week 16 is advised. Different modalities—including paired Harvey–Bradshaw index (HBI) scores and biochemical markers such as CRP and faecal calprotectin, endoscopic or radiological evaluation—may be used to determine treatment effect. However, the feasibility and acceptability of repeating endoscopic or radiological evaluations within this time frame are likely to limit their utility in this context. Nonetheless, the well-recognised discrepancy between clinical and endoscopic remission in CD should be borne in mind. For example, a recent prospective study of UST induction showed an endoscopic remission rate at week 24 of 7.1%. The concurrent clinical remission rate was 39.5%<sup><a href="#ref-51">51</a></sup>. In summary, given the feasibility issues at play as well as the desire to use an objective marker in combination with symptoms<sup><a href="#ref-52">52</a></sup>, faecal calprotectin appears to be ideally placed<sup><a href="#ref-53">53</a></sup>. However, this can be applied only to patients with an elevated measurement at baseline.</p><p class="" id=d19351e741>If an adequate response is achieved, every-12-week dosing is considered appropriate, but in cases of partial response, every-8-week dosing is recommended. In circumstances where there is a deterioration or complete non-response, switching to another treatment (or surgery) is appropriate. However, it is recognised that in some patients a late response is seen, and given that patients may have already failed other therapies, it would be reasonable to persist and suggest a further every-8-week dose after week 16<sup><a href="#ref-54">54</a></sup>. Another factor for consideration is that rates of endoscopic response and healing appear to be more favourable in every-8-week rather than every-12-week dosing<sup><a href="#ref-55">55</a></sup>. Therefore, if there is any doubt as to which dosing regimen to use, literature supports a decision to opt for every-8-week dosing.</p><p class="" id=d19351e752>There is also scope to adjust the frequency of maintenance dosing, even once already established. Post-hoc analysis of randomised controlled trials and observational evidence support changing from every-12-week to every-8-week dosing if a loss of response is observed<sup><a href="#ref-54">54</a>,<a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>. Dosing frequency can be reduced from every 8 weeks to every 12 weeks if remission is sustained, although there are little data to show the effect of this.</p><p class="" id=d19351e765>Another important practical factor for clinical use was addressed by a retrospective Canadian study that examined the rates of peri-operative complications associated with the use of UST (20 patients) compared with anti-TNF therapy (40 patients). Their findings suggested that there was no difference between the two groups with a post-surgical follow-up of 6 months, although the UST cohort of patients were more likely to be on concomitant immunomodulatory therapy and were more often undergoing surgery as an emergency. These findings will be reassuring to clinicians but should be confirmed in prospective studies with a larger cohort of patients<sup><a href="#ref-58">58</a></sup>.</p><p class="" id=d19351e772><b><i>Measuring and monitoring.</i></b> Access to UST TDM is currently limited and therefore it has not yet been integrated into routine clinical practice. However, a dose-response relationship has been demonstrated, and measuring serum levels will most likely be a useful tool to guide maintenance dosing in the future<sup><a href="#ref-51">51</a>,<a href="#ref-56">56</a>,<a href="#ref-59">59</a></sup>. For example, one recent study showed higher UST levels in endoscopic responders at every study time point (weeks 4, 8, 16 and 24)<sup><a href="#ref-51">51</a></sup>. In addition, potential therapeutic thresholds have already been postulated. A post-hoc analysis of UNITI suggested that a maintenance serum trough level of UST in the range of 0.8 to 1.4 µg/mL predicted clinical remission at 6 months<sup><a href="#ref-56">56</a></sup>. However, for endoscopic remission, higher levels appear to be required. A recent study suggested that a minimum UST drug level of 1.9 µg/mL was necessary to achieve an endoscopic response at 6 months<sup><a href="#ref-51">51</a></sup>. Another study suggested that a maintenance trough concentration of more than 4.5 µg/mL at 26 weeks correlated with biomarker and endoscopic response<sup><a href="#ref-59">59</a></sup>. However, there exists some discrepancy between these observations; in the former study, only 1.6% of patients had a 26-week trough level over 4.5 µg/mL. This may reflect insufficient dosing even whilst on an every-8-week regimen<sup><a href="#ref-51">51</a></sup>. It is possible that, in some cases of non-response, intensification of the dosing regimen (outside of licence) from every 8 weeks to every 4 weeks provides more adequate drug exposure and increased remission rates. However, further research in this regard is needed. The variation in serum levels between studies could be explained by intra-assay variation and other factors such as high baseline albumin, lower baseline faecal calprotectin and female sex (which are shown to be independent predictors of higher levels during induction<sup><a href="#ref-51">51</a></sup>). Currently, UST level concentration assays are not commercially available on a wide scale, so despite the growing body of evidence, at present dose adjustments are made empirically.</p><p class="" id=d19351e813><b><i>Combination with a conventional immunosuppressant.</i></b> In patients who receive UST, immunogenicity rates appear to be low. In addition, the use of concomitant immunomodulatory therapy does not seem to affect serum concentrations. Both of these findings were observed in a comprehensive pharmacokinetic and pharmacodynamic analysis of the UNITI trials<sup><a href="#ref-56">56</a></sup>. A post-hoc analysis of the UNITI trial revealed anti-UST antibodies in just 2.3% of 1366 patients during a year of treatment. These low rates are mirrored in another study showing antibodies in roughly 2% of patients (1 of 57) at weeks 8 and 16<sup><a href="#ref-51">51</a>,<a href="#ref-56">56</a></sup>. The former study used a drug-tolerant assay, the latter a drug-sensitive assay. Although the use of concomitant immunomodulation does not appear to impact UST concentrations<sup><a href="#ref-56">56</a></sup>, prior exposure to anti-TNF agents and amount of previous anti-TNF exposure have been shown to negatively influence maintenance serum UST levels<sup><a href="#ref-51">51</a></sup>. It may be appropriate to consider discontinuation of immunomodulatory therapies after commencing UST if the sole reason for their use was to reduce immunogenicity.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19351e842>Unanswered questions and controversies</h2><p class="" id=d19351e845>Despite great strides in terms of understanding how best to use biologic agents, there remain many unanswered questions. For example, even though no clear evidence suggests that using UST or VDZ in combination with an immunosuppressant is beneficial, it must be remembered that this did not become apparent for IFX until a dedicated trial, specifically aiming to answer that question, had been conducted. This trial is yet to be conducted for UST or VDZ. We also have a relatively limited understanding of their efficacy for IBD manifestations such as perianal fistulation and pouchitis, and most of the data for these indications come from post-hoc analyses of randomised trials and observational studies. In addition, although there have been no signals of harm, we currently have a relatively limited understanding of their safety in pregnancy, a factor which can play a significant role in guiding treatment decisions.</p><p class="" id=d19351e848>An ongoing source of debate and controversy in the era of multiple biologic mechanisms is biologic sequencing. We now have to decide not only which mechanism—and, in the case of anti-TNF, which agent—to use first but also which mechanism to switch to in cases of treatment failure. Although it is can be clearly appreciated from their registration trials that VDZ and UST are less efficacious when used after anti-TNF, it is not yet clear whether the efficacy of the anti-TNF agents is diminished but prior exposure to novel biologics. There is also interest in the concept of combining biologic agents with differing and perhaps complementary mechanisms of action. For example, a trial is under way which combines VDZ, ADA and methotrexate for CD patients considered at high risk for complicated disease<sup><a href="#ref-60">60</a></sup>. Although biologic combination regimens currently appear unfeasible on a cost basis alone, the impact of biosimilar versions is likely to make this type of strategy more achievable in the future. Finally, we have some way to go in terms of predicting which patients would benefit most from biologic therapy. In an attempt to address this question, the currently recruiting Predicting Outcomes for Crohn’s Disease Using a Molecular Biomarker (PROFILE) study uses a biomarker panel to separate CD patients at diagnosis into two cohorts: those likely to develop severe disease and those predicted to have a milder disease course. Patients within each group will be randomly assigned to receive either combination therapy with an immunomodulator and IFX (“top down” treatment) from the point of diagnosis or a “step up” approach of an immunomodulator initially followed by IFX only in the case of refractory disease. The trialists predict that patients in the severe group will benefit more from biologic treatment from the point of diagnosis, and if this is proven correct, it is likely that biologic therapies will appear earlier in treatment algorithms for this group of patients.</p><p class="" id=d19351e855>One thing that appears certain is that the range of biologic (and small-molecule) agents available for the treatment of CD will continue to expand—and rapidly. With several novel agents in late-phase trials and many more in earlier phases, the degree of complexity when making treatment choices will increase. Most importantly, with it, so will the range of options we have to offer patients with CD.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19351e861>Conclusions</h2><p class="" id=d19351e864>Biologic therapies have completely changed the landscape of IBD care, and although there is renewed interest in small-molecule therapies, they appear likely to remain central to the management of patients with more severe or refractory disease. Despite this, there remains a great unmet need with many patients failing to respond to induction therapy or losing response after an initial improvement. Only through a broad spectrum of work carried out over many years were we able to fully appreciate the nuances necessary to optimise the effect of the anti-TNF agents. Indeed, we are still learning. Although some of this understanding can be extrapolated to help us maximise the benefit of novel biologics, such as VDZ and UST, an entirely new program of work is necessary. The fact that much of this research is already under way is cause for optimism and means that over time we will hopefully be able to meet the unmet need of patients with IBD.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d19351e1 class=n-a></a><h2 class=main-title id=d19570>Grant information</h2><p>The authors declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d19351e871 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d19751>References</h2><div class="section ref-list"><a name=d19351e871 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d19351e878 class=n-a></a>Vande Casteele N, Ferrante M, van Assche G, <i> et al.</i>: Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. <i>Gastroenterology.</i> 2015; <b>148</b>(7): 1320–9.e3. <a target=xrefwindow id=d19351e889 href="http://www.ncbi.nlm.nih.gov/pubmed/25724455">PubMed Abstract </a> | <a target=xrefwindow id=d19351e892 href="https://doi.org/10.1053/j.gastro.2015.02.031">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d19351e901 class=n-a></a>Vande Casteele N, Herfarth H, Katz J, <i> et al.</i>: American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. <i>Gastroenterology.</i> 2017; <b>153</b>(3): 835–857.e6. <a target=xrefwindow id=d19351e912 href="http://www.ncbi.nlm.nih.gov/pubmed/28774547">PubMed Abstract </a> | <a target=xrefwindow id=d19351e915 href="https://doi.org/10.1053/j.gastro.2017.07.031">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d19351e924 class=n-a></a>Paul S, Roblin X, Peyrin-Biroulet L: Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease. <i>Aliment Pharmacol Ther.</i> 2015; <b>42</b>(7): 939–40. <a target=xrefwindow id=d19351e932 href="http://www.ncbi.nlm.nih.gov/pubmed/26331560">PubMed Abstract </a> | <a target=xrefwindow id=d19351e935 href="https://doi.org/10.1111/apt.13335">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d19351e944 class=n-a></a>Gisbert JP, Chaparro M: Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. <i>Am J Gastroenterol.</i> 2013; <b>108</b>(9): 1426–38. <a target=xrefwindow id=d19351e952 href="http://www.ncbi.nlm.nih.gov/pubmed/23752881">PubMed Abstract </a> | <a target=xrefwindow id=d19351e955 href="https://doi.org/10.1038/ajg.2013.171">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d19351e964 class=n-a></a>Mahadevan U, Wolf DC, Dubinsky M, <i> et al.</i>: Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. <i>Clin Gastroenterol Hepatol.</i> 2013; <b>11</b>(3): 286–92; quiz e24. <a target=xrefwindow id=d19351e975 href="http://www.ncbi.nlm.nih.gov/pubmed/23200982">PubMed Abstract </a> | <a target=xrefwindow id=d19351e978 href="https://doi.org/10.1016/j.cgh.2012.11.011">Publisher Full Text </a> | <a target=xrefwindow id=d19351e982 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3913646">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d19351e992 class=n-a></a>Zelinkova Z, de Haar C, de Ridder L, <i> et al.</i>: High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. <i>Aliment Pharmacol Ther.</i> 2011; <b>33</b>(9): 1053–8. <a target=xrefwindow id=d19351e1003 href="http://www.ncbi.nlm.nih.gov/pubmed/21366638">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1006 href="https://doi.org/10.1111/j.1365-2036.2011.04617.x">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d19351e1015 class=n-a></a>Julsgaard M, Christensen LA, Gibson PR, <i> et al.</i>: Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. <i>Gastroenterology.</i> 2016; <b>151</b>(1): 110–9. <a target=xrefwindow id=d19351e1026 href="http://www.ncbi.nlm.nih.gov/pubmed/27063728">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1029 href="https://doi.org/10.1053/j.gastro.2016.04.002">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d19351e1038 class=n-a></a>de Lima A, Zelinkova Z, van der Ent C, <i> et al.</i>: Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. <i>Gut.</i> 2016; <b>65</b>(8): 1261–8. <a target=xrefwindow id=d19351e1049 href="http://www.ncbi.nlm.nih.gov/pubmed/25966992">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1052 href="https://doi.org/10.1136/gutjnl-2015-309321">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d19351e1061 class=n-a></a>Seirafi M, de Vroey B, Amiot A, <i> et al.</i>: Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. <i>Aliment Pharmacol Ther.</i> 2014; <b>40</b>(4): 363–73. <a target=xrefwindow id=d19351e1072 href="http://www.ncbi.nlm.nih.gov/pubmed/24980270">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1075 href="https://doi.org/10.1111/apt.12833">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727423174"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1084 class=n-a></a>Seow CH, Leung Y, Vande Casteele N, <i> et al.</i>: The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. <i>Aliment Pharmacol Ther.</i> 2017; <b>45</b>(10): 1329–38. <a target=xrefwindow id=d19351e1095 href="http://www.ncbi.nlm.nih.gov/pubmed/28318043">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1098 href="https://doi.org/10.1111/apt.14040">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727423174">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d19351e1111 class=n-a></a>van der Woude CJ, Kanis SL: IBD: Exposure to anti-TNF agents in utero: controlling health risks. <i>Nat Rev Gastroenterol Hepatol.</i> 2016; <b>13</b>(7): 387–8. <a target=xrefwindow id=d19351e1119 href="http://www.ncbi.nlm.nih.gov/pubmed/27251210">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1122 href="https://doi.org/10.1038/nrgastro.2016.94">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d19351e1132 class=n-a></a>Kanis SL, de Lima-Karagiannis A, van der Ent C, <i> et al.</i>: Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. <i>J Crohns Colitis.</i> 2018; <b>12</b>(8): 939–47. <a target=xrefwindow id=d19351e1143 href="http://www.ncbi.nlm.nih.gov/pubmed/29771301">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1146 href="https://doi.org/10.1093/ecco-jcc/jjy058">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d19351e1155 class=n-a></a>Rahier JF, Magro F, Abreu C, <i> et al.</i>: Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. <i>J Crohns Colitis.</i> 2014; <b>8</b>(6): 443–68. <a target=xrefwindow id=d19351e1166 href="http://www.ncbi.nlm.nih.gov/pubmed/24613021">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1169 href="https://doi.org/10.1016/j.crohns.2013.12.013">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727286846"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1178 class=n-a></a>Mahadevan U, Vermeire S, Lasch K, <i> et al.</i>: Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. <i>Aliment Pharmacol Ther.</i> 2017; <b>45</b>(7): 941–50. <a target=xrefwindow id=d19351e1189 href="http://www.ncbi.nlm.nih.gov/pubmed/28169436">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1192 href="https://doi.org/10.1111/apt.13960">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727286846">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736209105"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1205 class=n-a></a>Scherl E, Jacobstein D, Murphy C, <i> et al.</i>: A109 Pregnancy Outcomes in Women Exposed to Ustekinumab in the Crohn’s Disease Clinical Development Program. <i>J Can Assoc Gastroenterol.</i> 2018; <b>1</b>(suppl_2): 166. <a target=xrefwindow id=d19351e1216 href="https://doi.org/10.1093/jcag/gwy009.109">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736209105">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d19351e1229 class=n-a></a>Feuerstein JD, Nguyen GC, Kupfer SS, <i> et al.</i>: American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. <i>Gastroenterology.</i> 2017; <b>153</b>(3): 827–34. <a target=xrefwindow id=d19351e1240 href="http://www.ncbi.nlm.nih.gov/pubmed/28780013">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1243 href="https://doi.org/10.1053/j.gastro.2017.07.032">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d19351e1252 class=n-a></a>Papamichael K, Osterman MT, Siegel CA, <i> et al.</i>: Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? <i>Gastroenterology.</i> 2018; <b>154</b>(4): 1201–2. <a target=xrefwindow id=d19351e1263 href="http://www.ncbi.nlm.nih.gov/pubmed/29432749">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1266 href="https://doi.org/10.1053/j.gastro.2018.01.001">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732442410"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1276 class=n-a></a>D’Haens G, Vermeire S, Lambrecht G, <i> et al.</i>: Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. <i>Gastroenterology.</i> 2018; <b>154</b>(5): 1343–1351.e1. <a target=xrefwindow id=d19351e1287 href="http://www.ncbi.nlm.nih.gov/pubmed/29317275">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1290 href="https://doi.org/10.1053/j.gastro.2018.01.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732442410">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733467492"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1303 class=n-a></a>El-Matary W, Walters TD, Huynh HQ, <i> et al.</i>: Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children. <i>Inflamm Bowel Dis.</i> 2019; <b>25</b>(1): 150–5. <a target=xrefwindow id=d19351e1314 href="http://www.ncbi.nlm.nih.gov/pubmed/29912413">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1317 href="https://doi.org/10.1093/ibd/izy217">Publisher Full Text </a> | <a target=xrefwindow id=d19351e1321 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6290776">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733467492">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727315173"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1334 class=n-a></a>Yarur AJ, Kanagala V, Stein DJ, <i> et al.</i>: Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. <i>Aliment Pharmacol Ther.</i> 2017; <b>45</b>(7): 933–40. <a target=xrefwindow id=d19351e1345 href="http://www.ncbi.nlm.nih.gov/pubmed/28211593">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1348 href="https://doi.org/10.1111/apt.13970">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727315173">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733114959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1361 class=n-a></a>Greener T, Kabakchiev B, Steinhart AH, <i> et al.</i>: Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease. <i>Inflamm Bowel Dis.</i> 2018; <b>24</b>(8): 1808–14. <a target=xrefwindow id=d19351e1372 href="http://www.ncbi.nlm.nih.gov/pubmed/29697810">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1375 href="https://doi.org/10.1093/ibd/izy066">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733114959">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732587739"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1388 class=n-a></a>Vermeire S, Gils A, Accossato P, <i> et al.</i>: Immunogenicity of biologics in inflammatory bowel disease. <i>Therap Adv Gastroenterol.</i> 2018; <b>11</b>: 1756283X1775035. <a target=xrefwindow id=d19351e1399 href="http://www.ncbi.nlm.nih.gov/pubmed/29383030">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1402 href="https://doi.org/10.1177/1756283X17750355">Publisher Full Text </a> | <a target=xrefwindow id=d19351e1406 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5784568">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732587739">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2953958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1419 class=n-a></a>Colombel JF, Sandborn WJ, Reinisch W, <i> et al.</i>: Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. <i>N Engl J Med.</i> 2010; <b>362</b>(15): 1383–95. <a target=xrefwindow id=d19351e1430 href="http://www.ncbi.nlm.nih.gov/pubmed/20393175">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1433 href="https://doi.org/10.1056/NEJMoa0904492">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2953958">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d19351e1447 class=n-a></a>Kennedy NA, Heap GA, Green HD: Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>Lancet Gastroenterol Hepatol.</i> 2019; <b>4</b>(5): 341–53. <a target=xrefwindow id=d19351e1455 href="http://www.ncbi.nlm.nih.gov/pubmed/30824404">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1458 href="https://doi.org/10.1016/S2468-1253(19)30012-3">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736209107"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1467 class=n-a></a>Roblin X, Paul S, Nancey S, <i> et al.</i>: 345 - Interest in the Addition of Azathioprine (AZA) to the Switch of Anti-TNF in IBD Patients in Clinical Relapse with Undetectable Anti-TNF trough Levels and Anti-Drug Antibodies: A Prospective Randomized Trial. <i>Gastroenterology.</i> 2018; <b>154</b>(Supplement 1): S–84. <a target=xrefwindow id=d19351e1478 href="https://doi.org/10.1016/S0016-5085(18)30731-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736209107">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725773141"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1491 class=n-a></a>Khanna R, Bressler B, Levesque BG, <i> et al.</i>: Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet.</i> 2015; <b>386</b>(10006): 1825–34. <a target=xrefwindow id=d19351e1502 href="http://www.ncbi.nlm.nih.gov/pubmed/26342731">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1505 href="https://doi.org/10.1016/S0140-6736(15)00068-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725773141">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733861794"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1518 class=n-a></a>Colombel JF, Adedokun OJ, Gasink C, <i> et al.</i>: Higher Levels of Infliximab may Alleviate the Need of Azathioprine Comedication in the Treatment of Patients with Crohn's Disease: A Sonic Post HOC Analysis. <i>Gastroenterology.</i> 2017; <b>152</b>(Supplement 1): S37–S38. <a target=xrefwindow id=d19351e1529 href="https://doi.org/10.1016/S0016-5085(17)30490-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733861794">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735131719"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1542 class=n-a></a>Drobne D, Kurent T, Golob S, <i> et al.</i>: Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. <i>Aliment Pharmacol Ther.</i> 2019; <b>49</b>(7): 880–9. <a target=xrefwindow id=d19351e1553 href="http://www.ncbi.nlm.nih.gov/pubmed/30784100">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1556 href="https://doi.org/10.1111/apt.15179">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735131719">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d19351e1569 class=n-a></a>Ma C, Huang V, Fedorak DK, <i> et al.</i>: Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. <i>Aliment Pharmacol Ther.</i> 2014; <b>40</b>(9): 1044–55. <a target=xrefwindow id=d19351e1580 href="http://www.ncbi.nlm.nih.gov/pubmed/25185992">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1583 href="https://doi.org/10.1111/apt.12940">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d19351e1593 class=n-a></a>Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease. <a target=xrefwindow id=d19351e1595 href="https://clinicaltrials.gov/ct2/show/NCT02065570">Reference Source</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d19351e1604 class=n-a></a>Yarur AJ, Jain A, Hauenstein SI, <i> et al.</i>: Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis. <i>Inflamm Bowel Dis.</i> 2016; <b>22</b>(2): 409–15. <a target=xrefwindow id=d19351e1615 href="http://www.ncbi.nlm.nih.gov/pubmed/26752470">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1618 href="https://doi.org/10.1097/MIB.0000000000000689">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727348937"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1627 class=n-a></a>Ward MG, Thwaites PA, Beswick L, <i> et al.</i>: Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. <i>Aliment Pharmacol Ther.</i> 2017; <b>45</b>(8): 1135–45. <a target=xrefwindow id=d19351e1638 href="http://www.ncbi.nlm.nih.gov/pubmed/28239869">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1641 href="https://doi.org/10.1111/apt.13992">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727348937">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734938397"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1654 class=n-a></a>Papamichael K, Juncadella A, Wong D, <i> et al.</i>: Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease. <i>J Crohns Colitis.</i> 2019. <a target=xrefwindow id=d19351e1662 href="http://www.ncbi.nlm.nih.gov/pubmed/30689771">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1665 href="https://doi.org/10.1093/ecco-jcc/jjz018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734938397">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d19351e1678 class=n-a></a>Matsumoto T, Motoya S, Watanabe K, <i> et al.</i>: Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. <i>J Crohns Colitis.</i> 2016; <b>10</b>(11): 1259–66. <a target=xrefwindow id=d19351e1689 href="http://www.ncbi.nlm.nih.gov/pubmed/27566367">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1692 href="https://doi.org/10.1093/ecco-jcc/jjw152">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733176055"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1701 class=n-a></a>Chan W, Lynch N, Bampton P, <i> et al.</i>: Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. <i>Eur J Gastroenterol Hepatol.</i> 2018; <b>30</b>(7): 735–40. <a target=xrefwindow id=d19351e1712 href="http://www.ncbi.nlm.nih.gov/pubmed/29727386">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1715 href="https://doi.org/10.1097/MEG.0000000000001150">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733176055">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733499076"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1729 class=n-a></a>Peyrin-Biroulet L, Danese S, Argollo M, <i> et al.</i>: Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(5): 838–846.e2. <a target=xrefwindow id=d19351e1740 href="http://www.ncbi.nlm.nih.gov/pubmed/29935327">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1743 href="https://doi.org/10.1016/j.cgh.2018.06.026">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733499076">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d19351e1756 class=n-a></a>Sierra Morales M, Birdi S, Samaan MA, <i> et al.</i>: P673 Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease. <i>J Crohns Colitis.</i> 2018; <b>12</b>(supplement_1): S451–S452. <a target=xrefwindow id=d19351e1767 href="https://doi.org/10.1093/ecco-jcc/jjx180.800">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718083272"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1776 class=n-a></a>Sandborn WJ, Feagan BG, Rutgeerts P, <i> et al.</i>: Vedolizumab as induction and maintenance therapy for Crohn's disease. <i>N Engl J Med.</i> 2013; <b>369</b>(8): 711–21. <a target=xrefwindow id=d19351e1787 href="http://www.ncbi.nlm.nih.gov/pubmed/23964933">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1790 href="https://doi.org/10.1056/NEJMoa1215739">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718083272">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718415285"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1803 class=n-a></a>Sands BE, Feagan BG, Rutgeerts P, <i> et al.</i>: Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. <i>Gastroenterology.</i> 2014; <b>147</b>(3): 618–627.e3. <a target=xrefwindow id=d19351e1814 href="http://www.ncbi.nlm.nih.gov/pubmed/24859203">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1817 href="https://doi.org/10.1053/j.gastro.2014.05.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718415285">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718083273"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1830 class=n-a></a>Feagan BG, Rutgeerts P, Sands BE, <i> et al.</i>: Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>N Engl J Med.</i> 2013; <b>369</b>(8): 699–710. <a target=xrefwindow id=d19351e1841 href="http://www.ncbi.nlm.nih.gov/pubmed/23964932">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1844 href="https://doi.org/10.1056/NEJMoa1215734">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718083273">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733256957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1857 class=n-a></a>Ward MG, Sparrow MP, Roblin X: Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. <i>Therap Adv Gastroenterol.</i> 2018; <b>11</b>: 1756284818772786. <a target=xrefwindow id=d19351e1865 href="http://www.ncbi.nlm.nih.gov/pubmed/29774052">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1868 href="https://doi.org/10.1177/1756284818772786">Publisher Full Text </a> | <a target=xrefwindow id=d19351e1871 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5949937">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733256957">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727038180"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1885 class=n-a></a>Williet N, Boschetti G, Fovet M, <i> et al.</i>: Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months. <i>Clin Gastroenterol Hepatol.</i> 2017; <b>15</b>(11): 1750–1757.e3. <a target=xrefwindow id=d19351e1896 href="http://www.ncbi.nlm.nih.gov/pubmed/27890854">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1899 href="https://doi.org/10.1016/j.cgh.2016.11.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727038180">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732587147"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1912 class=n-a></a>Yacoub W, Williet N, Pouillon L, <i> et al.</i>: Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. <i>Aliment Pharmacol Ther.</i> 2018; <b>47</b>(7): 906–12. <a target=xrefwindow id=d19351e1923 href="http://www.ncbi.nlm.nih.gov/pubmed/29384209">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1926 href="https://doi.org/10.1111/apt.14548">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732587147">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732201986"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1939 class=n-a></a>Bian S, Dreesen E, Tang HT, <i> et al.</i>: Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time. <i>Inflamm Bowel Dis.</i> 2017; <b>23</b>(12): 2202–8. <a target=xrefwindow id=d19351e1950 href="http://www.ncbi.nlm.nih.gov/pubmed/29140943">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1953 href="https://doi.org/10.1097/MIB.0000000000001255">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732201986">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732279401"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1966 class=n-a></a>Ungar B, Kopylov U, Yavzori M, <i> et al.</i>: Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. <i>Clin Gastroenterol Hepatol.</i> 2018; <b>16</b>(5): 697–705.e7. <a target=xrefwindow id=d19351e1977 href="http://www.ncbi.nlm.nih.gov/pubmed/29223444">PubMed Abstract </a> | <a target=xrefwindow id=d19351e1980 href="https://doi.org/10.1016/j.cgh.2017.11.050">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732279401">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727432886"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e1993 class=n-a></a>Rosario M, French JL, Dirks NL, <i> et al.</i>: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease. <i>J Crohns Colitis.</i> 2017; <b>11</b>(8): 921–9. <a target=xrefwindow id=d19351e2004 href="http://www.ncbi.nlm.nih.gov/pubmed/28333288">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2007 href="https://doi.org/10.1093/ecco-jcc/jjx021">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727432886">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726158027"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e2020 class=n-a></a>Colombel JF, Sands BE, Rutgeerts P, <i> et al.</i>: The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut.</i> 2017; <b>66</b>(5): 839–51. <a target=xrefwindow id=d19351e2031 href="http://www.ncbi.nlm.nih.gov/pubmed/26893500">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2034 href="https://doi.org/10.1136/gutjnl-2015-311079">Publisher Full Text </a> | <a target=xrefwindow id=d19351e2038 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5531223">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726158027">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733218415"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e2052 class=n-a></a>Christensen B, Gibson PR, Micic D, <i> et al.</i>: Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(3): 486–93. <a target=xrefwindow id=d19351e2063 href="http://www.ncbi.nlm.nih.gov/pubmed/29751166">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2066 href="https://doi.org/10.1016/j.cgh.2018.04.060">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733218415">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d19351e2079 class=n-a></a>Gadhok R, Rao R, Honap S, <i> et al.</i>: P318 Ustekinumab: Early experience and medium-term outcomes from a UK multi-centre real-world cohort. <i>J Crohns Colitis.</i> 2019; <b>13</b>(Supplement_1): S260. <a target=xrefwindow id=d19351e2090 href="https://doi.org/10.1093/ecco-jcc/jjy222.442">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727365276"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e2099 class=n-a></a>Ma C, Fedorak RN, Kaplan GG, <i> et al.</i>: Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort. <i>Aliment Pharmacol Ther.</i> 2017; <b>45</b>(9): 1232–43. <a target=xrefwindow id=d19351e2110 href="http://www.ncbi.nlm.nih.gov/pubmed/28252210">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2113 href="https://doi.org/10.1111/apt.14016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727365276">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735005626"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e2126 class=n-a></a>Verstockt B, Dreesen E, Noman M, <i> et al.</i>: Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates. <i>J Crohns Colitis.</i> 2019. <a target=xrefwindow id=d19351e2134 href="http://www.ncbi.nlm.nih.gov/pubmed/30715258">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2137 href="https://doi.org/10.1093/ecco-jcc/jjz008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735005626">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d19351e2150 class=n-a></a>Peyrin-Biroulet L, Sandborn W, Sands BE, <i> et al.</i>: Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>Am J Gastroenterol.</i> 2015; <b>110</b>(9): 1324–38. <a target=xrefwindow id=d19351e2161 href="http://www.ncbi.nlm.nih.gov/pubmed/26303131">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2164 href="https://doi.org/10.1038/ajg.2015.233">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d19351e2173 class=n-a></a>Pouillon L, Peyrin-Biroulet L: It is Time to Revise the STRIDE Guidelines Determining Therapeutic Goals for Treat-to-Target in Inflammatory Bowel Disease. <i>J Crohns Colitis.</i> 2018; <b>12</b>(4): 509. <a target=xrefwindow id=d19351e2181 href="http://www.ncbi.nlm.nih.gov/pubmed/29309565">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2184 href="https://doi.org/10.1093/ecco-jcc/jjx174">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d19351e2194 class=n-a></a>Sands B, Gasink C, Jacobstein D, <i> et al.</i>: Efficacy &amp; safety of dose adjustment &amp; delayed response to ustekinumab in moderate-severe crohn’s disease patients: results from im-uniti maintenance study. <i>Gut.</i> 2017; <b>66</b>(Suppl 2): A23. <a target=xrefwindow id=d19351e2205 href="https://gut.bmj.com/content/66/Suppl_2/A23.1">Reference Source</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733463140"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e2214 class=n-a></a>Rutgeerts P, Gasink C, Chan D, <i> et al.</i>: Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. <i>Gastroenterology.</i> 2018; <b>155</b>(4): 1045–58. <a target=xrefwindow id=d19351e2225 href="http://www.ncbi.nlm.nih.gov/pubmed/29909019">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2228 href="https://doi.org/10.1053/j.gastro.2018.06.035">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733463140">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732615064"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e2241 class=n-a></a>Adedokun OJ, Xu Z, Gasink C, <i> et al.</i>: Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. <i>Gastroenterology.</i> 2018; <b>154</b>(6): 1660–71. <a target=xrefwindow id=d19351e2252 href="http://www.ncbi.nlm.nih.gov/pubmed/29409871">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2255 href="https://doi.org/10.1053/j.gastro.2018.01.043">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732615064">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727432907"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e2268 class=n-a></a>Ma C, Fedorak RN, Kaplan GG, <i> et al.</i>: Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. <i>Inflamm Bowel Dis.</i> 2017; <b>23</b>(5): 833–9. <a target=xrefwindow id=d19351e2279 href="http://www.ncbi.nlm.nih.gov/pubmed/28328624">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2282 href="https://doi.org/10.1097/MIB.0000000000001074">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727432907">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736209194"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e2295 class=n-a></a>Shim HH, Ma C, Kotze PG, <i> et al.</i>: Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn’s Disease: A Canadian Multi-Centre Observational Cohort Study. <i>J Can Assoc Gastroenterol.</i> 2018; <b>1</b>(3): 115–23. <a target=xrefwindow id=d19351e2306 href="http://www.ncbi.nlm.nih.gov/pubmed/31294352">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2309 href="https://doi.org/10.1093/jcag/gwy013">Publisher Full Text </a> | <a target=xrefwindow id=d19351e2313 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6507292">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736209194">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727471699"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19351e2326 class=n-a></a>Battat R, Kopylov U, Bessissow T, <i> et al.</i>: Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. <i>Clin Gastroenterol Hepatol.</i> 2017; <b>15</b>(9): 1427–1434.e2. <a target=xrefwindow id=d19351e2337 href="http://www.ncbi.nlm.nih.gov/pubmed/28365485">PubMed Abstract </a> | <a target=xrefwindow id=d19351e2340 href="https://doi.org/10.1016/j.cgh.2017.03.032">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727471699">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d19351e2354 class=n-a></a>Triple Combination Therapy in High Risk Crohn's Disease (CD). <a target=xrefwindow id=d19351e2356 href="https://clinicaltrials.gov/ct2/show/NCT02764762">Reference Source</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Jul 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1210&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1210&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK<br/> <sup>2</sup> Department of Gastroenterology, Royal Free London NHS Foundation Trust, London, UK<br/> <sup>3</sup> Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK<br/> <p> <div class=margin-bottom> Mark Samaan <br/> <span>Roles: </span> Conceptualization, Project Administration, Writing – Original Draft Preparation </div> <div class=margin-bottom> Samantha Campbell <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Georgina Cunningham <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Aravind Gokul Tamilarasan <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Peter M. Irving <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Sara McCartney <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1210/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 29 Jul 2019, 8:1210 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.18902.1">https://doi.org/10.12688/f1000research.18902.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Samaan M <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=20718 data-id=18902 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18902.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1210/v1/pdf?article_uuid=ab6d8447-6e3d-4647-9264-28fb5517b7dd" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.18902.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Samaan M, Campbell S, Cunningham G <em>et al.</em> Biologic therapies for Crohn’s disease: optimising the old and maximising the new [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1210 (<a href="https://doi.org/10.12688/f1000research.18902.1" target=_blank>https://doi.org/10.12688/f1000research.18902.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=18902 id=mobile-track-article-signin-18902 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18902?target=/articles/8-1210"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20718 /> <input name=articleId type=hidden value=18902 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Alan Moss</strong>, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Consultant to Janssen and Pfizer (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Eduard Stange</strong>, Department of Internal Medicine, University of Tuebingen, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Jul 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1210&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1210&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=37475-51727></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=54303-51750></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1210/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>29 Jul 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Alan Moss</strong>, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Consultant to Janssen and Pfizer </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Eduard Stange</strong>, Department of Internal Medicine, University of Tuebingen, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1210&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1210/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Biologic therapies for Crohn\u2019s disease:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1210/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1210/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1210/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Samaan M et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1210/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1210",
            templates : {
                twitter : "Biologic therapies for Crohn\u2019s disease: optimising the old.... Samaan M et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1210/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Biologic therapies for Crohn\u2019s disease: optimising the old and maximising the new", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Biologic therapies for Crohn\u2019s disease: optimising the old and maximising the new", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/18902/20718")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "20718");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "51750": 1,
                           "51727": 3,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "8dcad9a1-04bc-403b-88a7-7dbe9cbe39c7";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1210.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1210.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1210.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1210.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1210.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>